Sponsor Check › Person
Related person on Form D filings · address states as listed: CA, NJ, RI, WA, OH, CO, MA, L2, PA, IN · listed Apr 24, 2009 → Jun 30, 2026
Data last updated: Oct 23, 2026, 5:45 PM ET · Courts (RECAP) last checked: Oct 24, 2026, 12:09 AM ET · SEC enforcement last checked: not yet
Privacy: business-related public information only. Residential addresses are never shown; only the state from the filing.
The five facts investors ask about first. Each section states what was searched and when. Items still in human review are not shown.
None found in sources searched.
Sources searched: CourtListener bulk data (RECAP dockets as of 2026-09-30) — federal district + bankruptcy courts; live RECAP re-check pending. State courts: not yet searched. PACER: not searched. · Last checked Oct 24, 2026, 12:09 AM ET.
State courts: not yet searched. No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.
SEC enforcement searched: SEC litigation releases and administrative proceedings — respondent names in the sec.gov index titles (30,205 releases, 1995-09-19 to 2026-10-23); release text is read only to confirm a candidate. Names that appear only in the body of a release are not found. — not yet searched; State securities regulators searched: AZ (Corporation Commission Securities Division), CA (DFPI — 16 of 12,159 DFPI respondent pages read so far; sponsor-name matches are read first), DE (DOJ Investor Protection Unit), TX (State Securities Board), WA (DFI) — last crawled Oct 23, 2026, 9:57 PM ET. Other states: not yet searched.
Not yet searched.
Search queued. Results are added automatically; check back later or follow this page to be notified.
None found in sources searched.
Sources searched: Federal bankruptcy courts via CourtListener / RECAP archive (federal district courts, federal bankruptcy courts). State courts: not yet searched. PACER: not searched (RECAP only). · Last checked Oct 24, 2026, 12:09 AM ET.
State courts: not yet searched. No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.
Comparisons are made for sponsors and sponsor groups, not individual people.
3 of 59 offerings report sales commissions totalling $2,091,400; 0 report finder's fees; 1 reports proceeds to related persons totalling $2,242,956. (includes amounts the issuer reported as estimates)
| Source | Offering (latest filing) | Sales commissions | Finder's fees | To insiders | Paid to sell it |
|---|---|---|---|---|---|
| EDGAR ↗ | Jun 30, 2026 D File 021-589142 | $0 (est.) | $0 | $0 The general partner is entitled to a performance allocation. The investment manager is entitled to a management fee. The performance allocation and management fee are fully discussed in the Issuer's confidential offering materials. | XT CAPITAL PARTNERS, LLC BrokerCheck CRD 118719 ↗ |
| EDGAR ↗ | Jan 29, 2026 D File 021-571698 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Mar 17, 2025 D File 021-541158 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Nov 18, 2022 D File 021-465364 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Mar 18, 2022 D File 021-438073 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Oct 15, 2021 D File 021-417090 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Dec 30, 2020 D File 021-384864 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Nov 20, 2020 D File 021-381115 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jul 7, 2020 D File 021-370375 | $350,000 | $0 | $0 | H.C. Wainwright & Co., LLC BrokerCheck CRD 375 ↗ |
| EDGAR ↗ | Jun 12, 2020 D File 021-368874 | $350,000 | $0 | $0 | H.C. Wainwright & Co., LLC BrokerCheck CRD 375 ↗ |
| EDGAR ↗ | Apr 3, 2020 D File 021-364301 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jan 31, 2020 D File 021-359530 | $1,391,400 | $0 | $0 | SVB Leerink LLC BrokerCheck CRD 39011 ↗ |
| EDGAR ↗ | Dec 17, 2019 D File 021-355633 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Oct 22, 2019 D File 021-351627 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Sep 6, 2019 D File 021-348117 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Apr 11, 2019 D File 021-337105 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Mar 28, 2019 D File 021-335883 | $0 | $0 | $0 | N/A no CRD number reported |
| EDGAR ↗ | Nov 20, 2018 D File 021-326260 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jul 12, 2018 D File 021-316724 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jun 12, 2018 D File 021-314375 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Apr 10, 2018 D/A File 021-300817 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Apr 9, 2018 D/A File 021-300820 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Mar 13, 2018 D File 021-307559 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Mar 2, 2018 D/A File 021-287819 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Nov 1, 2017 D File 021-297918 | $0 | $0 | $0 The General Partner receives a fee for advisory services. The fee is generally a percentage of the aggregate subscriptions of the Issuer's limited partners (as set forth in the Issuer's partnership agreement). | None listed on this filing |
| EDGAR ↗ | Mar 21, 2017 D File 021-282968 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Feb 22, 2017 D/A File 021-229888 | $0 | $0 | $2,242,956 | N/A no CRD number reported |
| EDGAR ↗ | Dec 30, 2016 D/A File 021-252227 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Oct 18, 2016 D File 021-272793 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Apr 4, 2016 D File 021-260605 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Mar 23, 2016 D/A File 021-250280 | $0 | $0 | $0 Frazier Management, L.L.C. receives a fee for advisory services. The fee is generally a percentage of the aggregate subscriptions of the issuer's LPs. | None listed on this filing |
| EDGAR ↗ | Mar 23, 2016 D File 021-259794 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Oct 29, 2015 D File 021-250272 | $0 | $0 | $0 The General Partner receives a fee for advisory services. The fee is generally a percentage of the aggregate subscriptions of the Issuer's limited partners (as set forth in the Issuer's partnership agreement). | None listed on this filing |
| EDGAR ↗ | Oct 14, 2015 D File 021-249352 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jun 23, 2015 D File 021-242328 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Mar 13, 2015 D File 021-235865 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Feb 17, 2015 D File 021-234129 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Sep 30, 2014 D File 021-225512 | $0 (est.) | $0 (est.) | $0 (est.) | None listed on this filing |
| EDGAR ↗ | Sep 23, 2014 D/A File 021-91597 | $0 (est.) | $0 (est.) | $0 (est.) | None listed on this filing |
| EDGAR ↗ | Sep 12, 2014 D File 021-224578 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jun 17, 2014 D File 021-219307 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jun 17, 2014 D File 021-219340 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Oct 2, 2013 D File 021-203887 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Sep 30, 2013 D/A File 021-180706 | $0 | $0 | $0 (est.) An affiliate of the General Partner will receive an investment advisory fee payable by the Issuer quarterly in advance. The investment advisory fee will generally be equal to a percentage of commitments as specified in the Issuer's constituent agreement. | None listed on this filing |
| EDGAR ↗ | Jun 14, 2013 D/A File 021-159955 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | May 8, 2013 D File 021-196141 | $0 | $0 | $0 (est.) The general partner or an affiliate thereof will receive a management fee payable by FH VII. | None listed on this filing |
| EDGAR ↗ | Nov 13, 2012 D/A File 021-177698 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Feb 24, 2012 D File 021-173910 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Mar 16, 2011 D File 021-156800 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Mar 11, 2011 D File 021-156607 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Mar 9, 2011 D File 021-156449 | $0 (est.) | $0 (est.) | $0 (est.) | None listed on this filing |
| EDGAR ↗ | Nov 24, 2010 D File 021-151020 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Nov 10, 2010 D File 021-150283 | $0 (est.) | $0 (est.) | $0 (est.) | None listed on this filing |
| EDGAR ↗ | Aug 30, 2010 D File 021-147084 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jul 14, 2010 D File 021-144909 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Mar 11, 2010 D File 021-107416 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Mar 8, 2010 D File 021-59559 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Sep 4, 2009 D File 021-67751 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Apr 24, 2009 D File 021-39151 | $0 | $0 | $0 | None listed on this filing |
As reported by the issuer on Form D (Items 12–15), latest filing per offering (one offering = one SEC file number; an amendment updates its offering rather than adding one). "To insiders" = gross proceeds used for payments to executive officers, directors or promoters. "—" = not reported on that filing. Amounts marked (est.) were reported as estimates. "Paid to sell it" = sales compensation recipients named on that filing (Item 12), each linked to FINRA BrokerCheck when a CRD number is reported.
Counted across every filing this person is listed on (latest filing per offering, per issuer).
| Source | Issuer | Role | Filed | Form | Offering | Sold | Investors | Min. investment |
|---|---|---|---|---|---|---|---|---|
| EDGAR ↗ | Frazier Life Sciences Public Fund, L.P. group: Frazier Healthcare | Executive Officer, Promoter Managing Member of the GP of the GP of the Issuer | Jun 30, 2026 | D | Indefinite similar: $155,000–$5,250,000 | $0 | 0 similar: 4–27 | No minimum reported similar: $1,000–$100,000 |
| EDGAR ↗ | Mirum Pharmaceuticals, Inc. | Director | Jan 29, 2026 | D | $68,480,000 similar: $2,000,000–$14,000,000 | $68,480,000 | 2 similar: 1–19 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Frazier Life Sciences XII, L.P. | Executive Officer Member of the General Partner of the General Partner | Mar 17, 2025 | D | Indefinite similar: $155,000–$5,250,000 | $0 | 0 similar: 4–27 | No minimum reported similar: $1,000–$100,000 |
| EDGAR ↗ | MBX Biosciences, Inc. | Director | Nov 18, 2022 | D | $115,184,430 similar: $1,694,259–$16,000,000 | $46,675,441 | 20 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | Frazier Life Sciences XI, L.P. | Executive Officer Member of the General Partner of the General Partner | Mar 18, 2022 | D | $960,000,000 similar: $155,000–$5,250,000 | $960,000,000 | 98 similar: 4–27 | No minimum reported similar: $1,000–$100,000 |
| EDGAR ↗ | Scout Bio, Inc. | Director | Oct 15, 2021 | D | $12,999,993 similar: $500,000–$7,000,000 | $4,750,005 | 6 similar: 2–14 | No minimum reported similar: $5,000–$50,000 |
| EDGAR ↗ | Mirum Pharmaceuticals, Inc. | Director | Dec 30, 2020 | D | $10,000,000 similar: $1,694,259–$16,000,000 | $10,000,000 | 3 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | Imago BioSciences, Inc. | Director | Nov 20, 2020 | D | $79,999,992 similar: $829,831–$9,999,998 | $79,999,992 | 28 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
| EDGAR ↗ | Iterum Therapeutics plc group: Iterum Therapeutics | Director | Jul 7, 2020 | D | $2,832,102 similar: $1,694,259–$16,000,000 | $2,832,102 | 8 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | Iterum Therapeutics plc group: Iterum Therapeutics | Director | Jun 12, 2020 | D | $2,844,627 similar: $1,694,259–$16,000,000 | $2,844,627 | 8 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | SutroVax, Inc. | Director | Apr 3, 2020 | D | $110,000,000 similar: $2,000,000–$19,999,994 | $110,000,000 | 23 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Iterum Therapeutics Bermuda Ltd group: Iterum Therapeutics | Director | Jan 31, 2020 | D | $51,588,000 similar: $1,694,259–$16,000,000 | $51,588,000 | 31 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | Frazier Life Sciences X, L.P. | Executive Officer Member of the General Partner of the General Partner | Dec 17, 2019 | D | $617,050,000 similar: $155,000–$5,250,000 | $0 | 0 similar: 4–27 | No minimum reported similar: $1,000–$100,000 |
| EDGAR ↗ | Arcutis Biotherapeutics, Inc. | Director | Oct 22, 2019 | D | $94,500,000 similar: $2,000,000–$19,999,994 | $94,499,967 | 16 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Passage BIO, Inc. | Director | Sep 6, 2019 | D | $110,000,000 similar: $829,831–$9,999,998 | $109,999,974 | 15 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
| EDGAR ↗ | Scout Bio, Inc. | Director | Apr 11, 2019 | D | $20,000,004 similar: $500,000–$7,000,000 | $20,000,004 | 6 similar: 2–14 | No minimum reported similar: $5,000–$50,000 |
| EDGAR ↗ | Imago BioSciences, Inc. | Director | Mar 28, 2019 | D | $39,999,994 similar: $829,831–$9,999,998 | $16,999,998 | 12 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
| EDGAR ↗ | Mirum Pharmaceuticals, Inc. | Director | Nov 20, 2018 | D | $120,063,750 similar: $1,694,259–$16,000,000 | $60,063,750 | 14 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | Recida Therapeutics, Inc. | Director | Jul 12, 2018 | D | $10,667,877 similar: $2,000,000–$19,999,994 | $5,667,877 | 1 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | SutroVax, Inc. | Director | Jun 12, 2018 | D | $85,682,959 similar: $2,000,000–$19,999,994 | $43,182,959 | 12 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Frazier Healthcare Growth Buyout Affiliates IX, L.P. group: Frazier Healthcare | Promoter Member of the Issuer's affiliated advisor, Frazier Management, L.L.C. | Apr 10, 2018 | D/A | Indefinite similar: $155,000–$5,250,000 | $6,440,000 | 33 similar: 4–27 | No minimum reported similar: $1,000–$100,000 |
| EDGAR ↗ | Frazier Healthcare Growth Buyout Fund IX, L.P. group: Frazier Healthcare | Promoter Member of the Issuers' affiliated advisor, Frazier Management, L.L.C. | Apr 9, 2018 | D/A | Indefinite similar: $155,000–$5,250,000 | $775,712,511 | 138 similar: 4–27 | No minimum reported similar: $1,000–$100,000 |
| EDGAR ↗ | Scout Bio, Inc. | Director | Mar 13, 2018 | D | $9,290,416 similar: $500,000–$7,000,000 | $9,290,416 | 4 similar: 2–14 | No minimum reported similar: $5,000–$50,000 |
| EDGAR ↗ | Iterum Therapeutics plc group: Iterum Therapeutics | Director | Mar 2, 2018 | D/A | $78,097,985 similar: $2,000,000–$19,999,994 | $78,097,985 | 17 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Frazier Healthcare Growth Buyout Fund IX, L.P. group: Frazier Healthcare | Promoter Member of the Issuers' affiliated advisor, Frazier Management, L.L.C. | Dec 14, 2017 | D | Indefinite similar: $155,000–$5,250,000 | $0 | 0 similar: 4–27 | No minimum reported similar: $1,000–$100,000 |
| EDGAR ↗ | Frazier Healthcare Growth Buyout Affiliates IX, L.P. group: Frazier Healthcare | Promoter Member of the Issuer's affiliated advisor, Frazier Management, L.L.C. | Dec 14, 2017 | D | Indefinite similar: $155,000–$5,250,000 | $0 | 0 similar: 4–27 | No minimum reported similar: $1,000–$100,000 |
| EDGAR ↗ | Frazier Life Sciences IX, L.P. group: Frazier Healthcare | Executive Officer Member of the general partner of the Issuer's general partner | Nov 1, 2017 | D | $418,925,000 similar: $155,000–$5,250,000 | $418,925,000 | 55 similar: 4–27 | No minimum reported similar: $1,000–$100,000 |
| EDGAR ↗ | Iterum Therapeutics plc group: Iterum Therapeutics | Director | Jun 1, 2017 | D | $65,524,992 similar: $2,000,000–$19,999,994 | $45,867,493 | 17 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | SutroVax, Inc. | Director | Mar 21, 2017 | D | $60,150,027 similar: $2,000,000–$19,999,994 | $40,100,007 | 9 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Imago BioSciences, Inc. | Director | Feb 22, 2017 | D/A | $40,499,995 similar: $829,831–$9,999,998 | $40,499,995 | 7 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
| EDGAR ↗ | Iterum Therapeutics plc group: Iterum Therapeutics | Director | Dec 30, 2016 | D/A | $47,640,000 similar: $2,000,000–$19,999,994 | $47,639,999 | 13 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Silvergate Pharmaceuticals, Inc. | Director | Oct 18, 2016 | D | $4,600,000 similar: $1,694,259–$16,000,000 | $4,600,000 | 10 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | Zavante Therapeutics, Inc. | Director | Apr 4, 2016 | D | $45,731,764 similar: $1,694,259–$16,000,000 | $45,731,764 | 54 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | Frazier Healthcare Growth Buyout Affiliates VIII, L.P. group: Frazier Healthcare | Promoter Member of the Issuer's affiliated advisor, Frazier Management, L.L.C. | Mar 23, 2016 | D | $5,000,000 similar: $155,000–$5,250,000 | $5,000,000 | 21 similar: 4–27 | $100,000 similar: $1,000–$100,000 |
| EDGAR ↗ | Frazier Healthcare Growth Buyout Fund VIII, L.P. group: Frazier Healthcare | Promoter Member of the Issuer's affiliated advisor, Frazier Management, L.L.C. | Mar 23, 2016 | D/A | $519,612,246 similar: $155,000–$5,250,000 | $519,612,246 | 67 similar: 4–27 | $75,000 similar: $1,000–$100,000 |
| EDGAR ↗ | Frazier Healthcare Growth Buyout Fund VIII, L.P. group: Frazier Healthcare | Promoter Member of the Issuer's affiliated advisor, Frazier Management, L.L.C. | Jan 12, 2016 | D/A | $500,000,000 similar: $155,000–$5,250,000 | $435,000,000 | 62 similar: 4–27 | $75,000 similar: $1,000–$100,000 |
| EDGAR ↗ | Iterum Therapeutics plc group: Iterum Therapeutics | Director | Dec 2, 2015 | D | $47,490,000 similar: $2,000,000–$19,999,994 | $23,790,001 | 12 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Frazier Healthcare Growth Buyout Fund VIII, L.P. group: Frazier Healthcare | Promoter Member of the Issuer's affiliated advisor, Frazier Management, L.L.C. | Oct 29, 2015 | D | Indefinite similar: $155,000–$5,250,000 | $0 | 0 similar: 4–27 | No minimum reported similar: $1,000–$100,000 |
| EDGAR ↗ | Frazier Life Sciences VIII, L.P. group: Frazier Healthcare | Executive Officer Member of the general partner of the Issuer's general partner | Oct 29, 2015 | D | $262,000,000 similar: $155,000–$5,250,000 | $262,000,000 | 46 similar: 4–27 | $68,750 similar: $1,000–$100,000 |
| EDGAR ↗ | Silvergate Pharmaceuticals, Inc. | Director | Oct 14, 2015 | D | $4,600,000 similar: $1,694,259–$16,000,000 | $1,600,000 | 9 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | Nexcida Therapeutics, Inc. | Director | Jun 23, 2015 | D | $21,250,003 similar: $500,000–$7,000,000 | $2,750,002 | 5 similar: 2–14 | No minimum reported similar: $5,000–$50,000 |
| EDGAR ↗ | COLLEGIUM PHARMACEUTICAL, INC | Director | Mar 13, 2015 | D | $50,000,000 similar: $1,694,259–$16,000,000 | $50,000,000 | 18 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | Cidara Therapeutics, Inc. group: Trius | Director | Feb 17, 2015 | D | $42,019,999 similar: $2,000,000–$19,999,994 | $42,019,999 | 19 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Imago BioSciences, Inc. | Director | Dec 11, 2014 | D | $26,499,997 similar: $829,831–$9,999,998 | $8,833,330 | 6 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
| EDGAR ↗ | VentiRx Pharmaceuticals Inc. | Director | Sep 30, 2014 | D | $15,000,000 similar: $2,000,000–$19,999,994 | $15,000,000 | 1 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | VentiRx Pharmaceuticals Inc. | Director | Sep 23, 2014 | D/A | $53,102,414 similar: $2,000,000–$19,999,994 | $50,602,514 | 9 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Silvergate Pharmaceuticals, Inc. | Director | Sep 12, 2014 | D | $1,000,000 similar: $1,694,259–$16,000,000 | $1,000,000 | 7 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | Cidara Therapeutics, Inc. group: Trius | Director | Jun 17, 2014 | D | $42,743,763 similar: $2,000,000–$19,999,994 | $30,332,199 | 8 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Cidara Therapeutics, Inc. group: Trius | Director | Jun 17, 2014 | D | $6,000,472 similar: $2,000,000–$19,999,994 | $6,000,472 | 1 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | COLLEGIUM PHARMACEUTICAL, INC | Director | Oct 2, 2013 | D | $12,000,000 similar: $1,694,259–$16,000,000 | $4,000,002 | 13 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | Frazier Healthcare VII, L.P. group: Frazier Healthcare | Executive Officer Member of the general partner of the Issuer's general partner | Sep 30, 2013 | D/A | $400,000,000 similar: $155,000–$5,250,000 | $293,943,299 | 37 similar: 4–27 | $50,000 similar: $1,000–$100,000 |
| EDGAR ↗ | Silvergate Pharmaceuticals, Inc. | Director | Jun 14, 2013 | D/A | $23,554,167 similar: $1,694,259–$16,000,000 | $23,554,167 | 13 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | Frazier Healthcare VII-A, L.P. group: Frazier Healthcare | Executive Officer Member of the general partner of the Issuer's general partner | May 8, 2013 | D | $82,500,000 similar: $155,000–$5,250,000 | $82,500,000 | 3 similar: 4–27 | $1,000,000 similar: $1,000–$100,000 |
| EDGAR ↗ | Precision Dermatology, Inc. | Director | Nov 13, 2012 | D/A | $58,100,001 | $55,000,001 | 0 | No minimum reported |
| EDGAR ↗ | Frazier Healthcare VII, L.P. group: Frazier Healthcare | Executive Officer Member of the general partner of the Issuer's general partner | Jul 3, 2012 | D | $400,000,000 | $0 | 0 | $1,000,000 |
| EDGAR ↗ | Precision Dermatology, Inc. | Director | May 4, 2012 | D | $40,000,000 | $29,400,001 | 0 | No minimum reported |
| EDGAR ↗ | VentiRx Pharmaceuticals Inc. | Director | Mar 8, 2012 | D/A | $25,000,002 | $18,750,001 | 5 | No minimum reported |
| EDGAR ↗ | COLLEGIUM PHARMACEUTICAL, INC | Director | Feb 24, 2012 | D | $22,461,190 similar: $1,694,259–$16,000,000 | $22,461,190 | 12 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | Silvergate Pharmaceuticals, Inc. | Director | May 17, 2011 | D | $3,015,000 similar: $1,694,259–$16,000,000 | $3,015,000 | 2 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | Informed Medical Communications, Inc. | Director | Mar 16, 2011 | D | $7,628,078 | $7,628,078 | 6 | No minimum reported |
| EDGAR ↗ | Informed Medical Communications, Inc. | Director | Mar 11, 2011 | D | $7,246,674 | $7,246,674 | 6 | No minimum reported |
| EDGAR ↗ | KALIDEX PHARMACEUTICALS, INC. | Director | Mar 9, 2011 | D | $44,999,989 similar: $1,694,259–$16,000,000 | $8,249,998 | 8 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | Precision Dermatology, Inc. | Director | Nov 24, 2010 | D | $20,000,001 similar: $1,694,259–$16,000,000 | $19,000,001 | 10 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | KALIDEX PHARMACEUTICALS, INC. | Director | Nov 10, 2010 | D | $500,628 similar: $1,694,259–$16,000,000 | $250,628 | 4 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | Tobira Therapeutics, Inc. | Director | Aug 30, 2010 | D | $31,199,776 | $14,199,776 | 6 | No minimum reported |
| EDGAR ↗ | Tobira Therapeutics, Inc. | Director | Jul 14, 2010 | D | $10,999,999 | $4,999,999 | 5 | No minimum reported |
| EDGAR ↗ | Tobira Therapeutics, Inc. | Director | Mar 11, 2010 | D | $4,000,000 | $4,000,000 | 5 | No minimum reported |
| EDGAR ↗ | COLLEGIUM PHARMACEUTICAL, INC | Director | Mar 8, 2010 | D | $2,500,000 similar: $1,694,259–$16,000,000 | $1,000,000 | 7 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | VentiRx Pharmaceuticals Inc. | Director | Jan 22, 2010 | D | $25,000,002 | $12,500,001 | 5 | $1 |
| EDGAR ↗ | Trubion Pharmaceuticals, Inc | Director | Sep 4, 2009 | D | $10,000,000 | $10,000,000 | 1 | $10,000,000 |
| EDGAR ↗ | QUATRX PHARMACEUTICALS Co | Director | Apr 24, 2009 | D | $37,055,718 similar: $1,694,259–$16,000,000 | $14,025,045 | 17 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
Every row is a Form D or D/A on which the issuer listed this name as a related person. Related-person names are matched on first + last name and the address state on the filing; records that share a name but could not be tied together by a second identifier are listed separately below.
"Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years (6 industry/exemption sets on this page); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
People and management entities the issuers listed as related persons on the same Form D filings as Patrick Heron. Source: the EDGAR rows in the table above. Showing the 40 with the most shared filings.
None found in sources searched.
Sources searched: SEC Regulation A Data Sets (Forms 1-A, 1-K, 1-Z; 2015 Q2 → 2026 Q3); SEC Crowdfunding Offerings Data Sets (Form C family; 2016 Q2 → 2026 Q3); EDGAR form index for 2026 Q3 → 2026 Q4 · Last checked Oct 23, 2026, 8:41 PM ET.
Export this report as PDF (members · included free during the launch period)
No corrections have been requested for this page.
Free. Logged with status: received → under review → fixed / confirmed with source.
If this is you or your firm, add a sourced explanation next to any fact. Reviewed before publishing.
Members get an email when Patrick Heron appears on a new Form D, or when a court case or SEC action is matched to them. See plans →